Dividend Information About Revvity: Everything You Need to Know Before Its Ex-Dividend Date on Oct 17, 2025

Generated by AI AgentAinvest Dividend Digest
Monday, Oct 13, 2025 7:08 pm ET1min read
RVTY--
Aime RobotAime Summary

- Revvity announced a $0.0700/share dividend with ex-dividend date Oct 17, 2025, below its 10-year average of $0.1035.

- The company closed a Massachusetts facility and reported layoffs via WARN act, signaling operational restructuring.

- A partnership with Sanofi for a Type 1 diabetes diagnostic test aims to expand market reach beyond rare diseases.

- J.P. Morgan maintains a $100 price target while analysts raise optimism to $92, citing valuation potential post-restructuring.

Revvity (RVTY) has recently announced its upcoming cash dividend, with the ex-dividend date set for Oct 17, 2025. Investors who wish to receive the $0.0700 per share payout must purchase the stock before this date, as the record date will determine eligibility for the dividend, which is scheduled to be paid on Nov 7, 2025. The dividend announcement was made on Jul 24, 2025, and the amount is slightly lower than the average of the last 10 dividend payments, which stood at $0.1035 per share. The last cash dividend was distributed on Aug 8, 2025, also at $0.0700 per share, indicating some stability in the company’s dividend pattern.

Over the past week, several developments have shaped the company’s recent trajectory. RevvityRVTY-- recently closed its second facility in Massachusetts, a move that aligns with its ongoing restructuring efforts and reportedly led to additional layoffs. This decision, detailed in a Worker Adjustment and Retraining Notification (WARN), signals a strategic shift in its operational footprint. Additionally, J.P. Morgan analysts recently reiterated a Hold rating for the company, maintaining a price target of $100.00 per share, suggesting that while the stock remains stable, significant upward movement is not expected in the near term. Another notable development is the company’s recent partnership with Sanofi to develop a diagnostic test for the early detection of Type 1 diabetes, a move that could expand Revvity’s market reach beyond rare diseases and potentially enhance its long-term growth prospects.

Since the last update, Revvity has demonstrated modest volatility in its stock performance, with analysts noting 11 instances of more than 5% price swings over the past year. Despite this, the stock has seen a modest recovery in recent days, prompting evaluations of its valuation potential. Meanwhile, analysts have raised the target price to $92.00, reflecting a more optimistic outlook on its fundamentals and operational adjustments. Investors are closely watching these developments to gauge the company’s ability to stabilize operations and improve profitability. It is important to note that the ex-dividend date of Oct 17, 2025, marks the final opportunity for investors to purchase shares and receive the upcoming dividend. Any shares acquired after this date will not be eligible for the $0.0700 per share payout.

Sip from the stream of US stock dividends. Your income play.

Latest Articles

Stay ahead of the market.

Get curated U.S. market news, insights and key dates delivered to your inbox.

Comments



Add a public comment...
No comments

No comments yet